Cargando…

Moderate- to high-intensity exercise does not modify cortical β-amyloid in Alzheimer's disease

INTRODUCTION: Animal models of Alzheimer's disease show that exercise may modify β-amyloid (Aβ) deposition. We examined the effect of a 16-week exercise intervention on cortical Aβ in patients with mild-to-moderate Alzheimer's disease. METHODS: Thirty-six patients with Alzheimer's dis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Frederiksen, Kristian S., Madsen, Karine, Andersen, Birgitte B., Beyer, Nina, Garde, Ellen, Høgh, Peter, Waldemar, Gunhild, Hasselbalch, Steen G., Law, Ian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Featured Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6556817/ https://www.ncbi.nlm.nih.gov/pubmed/31198839 http://dx.doi.org/10.1016/j.trci.2019.04.006

Ejemplares similares

A 16-Week Aerobic Exercise Intervention Does Not Affect Hippocampal Volume and Cortical Thickness in Mild to Moderate Alzheimer’s Disease
por: Frederiksen, Kristian Steen, et al.
Publicado: (2018)

Patients with Alzheimer's disease who carry the APOE ε4 allele benefit more from physical exercise
por: Jensen, Camilla Steen, et al.
Publicado: (2019)

The role of physical and cognitive function in performance of activities of daily living in patients with mild-to-moderate Alzheimer’s disease – a cross-sectional study
por: Clemmensen, Frederikke K, et al.
Publicado: (2020)

Physical Exercise May Increase Plasma Concentration of High-Density Lipoprotein-Cholesterol in Patients With Alzheimer’s Disease
por: Jensen, Camilla Steen, et al.
Publicado: (2020)

Change in Fitness and the Relation to Change in Cognition and Neuropsychiatric Symptoms After Aerobic Exercise in Patients with Mild Alzheimer’s Disease
por: Sobol, Nanna A., et al.
Publicado: (2018)

Aerobic exercise does not affect serum neurofilament light in patients with mild Alzheimer’s disease
por: Frederiksen, Kristian Steen, et al.
Publicado: (2023)

Effect of physical exercise on markers of neuronal dysfunction in cerebrospinal fluid in patients with Alzheimer's disease
por: Jensen, Camilla Steen, et al.
Publicado: (2017)

Resting State EEG in Exercise Intervention Studies: A Systematic Review of Effects and Methods
por: Gramkow, Mathias Holsey, et al.
Publicado: (2020)

Cost-effectiveness of a randomised trial of physical activity in Alzheimer’s disease: a secondary analysis exploring patient and proxy-reported health-related quality of life measures in Denmark
por: Sopina, Elizaveta, et al.
Publicado: (2017)

Comparison of the clinical impact of 2-[(18)F]FDG-PET and cerebrospinal fluid biomarkers in patients suspected of Alzheimer’s disease
por: Gjerum, Le, et al.
Publicado: (2021)

Prognostic value of complementary biomarkers of neurodegeneration in a mixed memory clinic cohort
por: Gramkow, Mathias Holsey, et al.
Publicado: (2020)

The effect of physical exercise on cerebral blood flow in Alzheimer's disease
por: van der Kleij, Lisa A., et al.
Publicado: (2018)

The Cortical Signature of Alzheimer's Disease: Regionally Specific Cortical Thinning Relates to Symptom Severity in Very Mild to Mild AD Dementia and is Detectable in Asymptomatic Amyloid-Positive Individuals
por: Dickerson, Bradford C., et al.
Publicado: (2009)

Estimation of brain amyloid accumulation using deep learning in clinical [(11)C]PiB PET imaging
por: Ladefoged, Claes Nøhr, et al.
Publicado: (2023)

Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum
por: Milà‐Alomà, Marta, et al.
Publicado: (2020)

Progression of Blood-Brain Barrier Leakage in Patients with Alzheimer’s Disease as Measured with the Cerebrospinal Fluid/Plasma Albumin Ratio Over Time
por: Musaeus, Christian Sandøe, et al.
Publicado: (2023)

Distinct effects of beta‐amyloid and tau on cortical thickness in cognitively healthy older adults
por: Harrison, Theresa M., et al.
Publicado: (2020)

Cerebral amyloid‐β load is associated with neurodegeneration and gliosis: Mediation by p‐tau and interactions with risk factors early in the Alzheimer's continuum
por: Salvadó, Gemma, et al.
Publicado: (2021)

Ganglion cell layer thinning in prodromal Alzheimer's disease defined by amyloid PET
por: López-de-Eguileta, Alicia, et al.
Publicado: (2019)

Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study
por: Lopes Alves, Isadora, et al.
Publicado: (2020)

Enrichment factors for clinical trials in mild-to-moderate Alzheimer's disease
por: Ballard, Clive, et al.
Publicado: (2019)

Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease
por: Schott, Jonathan M., et al.
Publicado: (2016)

Biochemical Markers of Physical Exercise on Mild Cognitive Impairment and Dementia: Systematic Review and Perspectives
por: Jensen, Camilla Steen, et al.
Publicado: (2015)

Detection of Alzheimer's disease amyloid beta 1‐42, p‐tau, and t‐tau assays
por: van Harten, Argonde C., et al.
Publicado: (2021)

Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy
por: Landen, Jaren W., et al.
Publicado: (2017)

The impact of the COVID-19 pandemic on mortality in people with dementia without COVID-19: a systematic review and meta-analysis
por: Axenhus, Michael, et al.
Publicado: (2022)

Lactoferrin in cerebrospinal fluid and saliva is not a diagnostic biomarker for Alzheimer's disease in a mixed memory clinic population
por: Gleerup, Helena Sophia, et al.
Publicado: (2021)

Comparing a Single Clinician Versus a Multidisciplinary Consensus Conference Approach for Dementia Diagnostics
por: Thorlacius-Ussing, Gorm, et al.
Publicado: (2021)

Alzheimer's disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer's disease trials of bapineuzumab
por: Samtani, Mahesh N., et al.
Publicado: (2015)

UB-311, a novel UBITh(®) amyloid β peptide vaccine for mild Alzheimer's disease
por: Wang, Chang Yi, et al.
Publicado: (2017)

Normal cerebrospinal fluid concentrations of PDGFRβ in patients with cerebral amyloid angiopathy and Alzheimer's disease
por: De Kort, Anna M., et al.
Publicado: (2021)

Two randomized controlled trials of SB742457 in mild-to-moderate Alzheimer's disease
por: Maher-Edwards, Gareth, et al.
Publicado: (2015)

APP accumulates with presynaptic proteins around amyloid plaques: A role for presynaptic mechanisms in Alzheimer's disease?
por: Jordà‐Siquier, Tomàs, et al.
Publicado: (2022)

Ponezumab in mild-to-moderate Alzheimer's disease: Randomized phase II PET-PIB study
por: Landen, Jaren W., et al.
Publicado: (2017)

Effects of aerobic exercise on event-related potentials related to cognitive performance: a systematic review
por: Gusatovic, Julia, et al.
Publicado: (2022)

Learning from amyloid trials in Alzheimer's disease. A virtual patient analysis using a quantitative systems pharmacology approach
por: Geerts, Hugo, et al.
Publicado: (2020)

The ALFA project: A research platform to identify early pathophysiological features of Alzheimer's disease
por: Molinuevo, José Luis, et al.
Publicado: (2016)

A phase 2 randomized, controlled trial of the α7 agonist ABT-126 in mild-to-moderate Alzheimer's dementia
por: Gault, Laura M., et al.
Publicado: (2015)

Changes in the left temporal microstate are a sign of cognitive decline in patients with Alzheimer’s disease
por: Musaeus, Christian S., et al.
Publicado: (2020)

Quantitative Electroencephalography Analyzed by Statistical Pattern Recognition as a Diagnostic and Prognostic Tool in Mild Cognitive Impairment: Results from a Nordic Multicenter Cohort Study
por: Schjønning Nielsen, Malene, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ukfs0kmlep4e5ciudjskh9m20v